These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 7378257)

  • 21. Effect of thyrotoxicosis on liver blood flow and propranolol disposition after long-term dosing.
    Wells PG; Feely J; Wilkinson GR; Wood AJ
    Clin Pharmacol Ther; 1983 May; 33(5):603-8. PubMed ID: 6839632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver size in evaluating drug metabolizing capacity in man.
    Pirttiaho H
    Int J Clin Pharmacol Biopharm; 1979 Jun; 17(6):271-6. PubMed ID: 468452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis.
    Olanoff LS; Walle T; Cowart TD; Walle UK; Oexmann MJ; Conradi EC
    Clin Pharmacol Ther; 1986 Oct; 40(4):408-14. PubMed ID: 3757404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug metabolism in diabetic subjects with fatty livers.
    Pirttiaho HI; Salmela PI; Sotaniemi EA; Pelkonen RO; Pitkänen U; Luoma PV
    Br J Clin Pharmacol; 1984 Dec; 18(6):895-9. PubMed ID: 6529530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of halothane on drug disposition: contribution of changes in intrinsic drug metabolizing capacity and hepatic blood flow.
    Reilly CS; Wood AJ; Koshakji RP; Wood M
    Anesthesiology; 1985 Jul; 63(1):70-6. PubMed ID: 4014773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clearance by the liver in cirrhosis. I. Relationship between propranolol metabolism in vitro and its extraction by the perfused liver in the rat.
    Fenyves D; Gariépy L; Villeneuve JP
    Hepatology; 1993 Feb; 17(2):301-6. PubMed ID: 8428728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The inhibitory effect of propranolol pretreatment on its own metabolism in the rat.
    Schneck DW; Pritchard JF
    J Pharmacol Exp Ther; 1981 Sep; 218(3):575-81. PubMed ID: 6267246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease.
    Vuitton D; Miguet JP; Camelot G; Delafin C; Joanne C; Bechtel P; Gillet M; Carayon P
    Gastroenterology; 1981 Jan; 80(1):112-8. PubMed ID: 7450397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intact hepatocyte theory of impaired drug metabolism in experimental cirrhosis in the rat.
    Wood AJ; Villeneuve JP; Branch RA; Rogers LW; Shand DG
    Gastroenterology; 1979 Jun; 76(6):1358-62. PubMed ID: 437433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regio- and stereoselective propranolol metabolism by 15 forms of purified cytochromes P-450 from rat liver.
    Fujita S; Umeda S; Funae Y; Imaoka S; Abe H; Ishida R; Adachi T; Masuda M; Kazusaka A; Suzuki T
    J Pharmacol Exp Ther; 1993 Jan; 264(1):226-33. PubMed ID: 8423527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liver size and indices of drug metabolism in alcoholics.
    Pirttiaho HI; Sotaniemi EA; Ahlqvist J; Pitkänen U; Pelkonen RO
    Eur J Clin Pharmacol; 1978 Mar; 13(1):61-7. PubMed ID: 639835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of age on the hepatic clearance of propranolol in rats.
    Iwamoto K; Watanabe J; Araki K; Deguchi N; Sugiyama H
    J Pharm Pharmacol; 1985 Jul; 37(7):466-70. PubMed ID: 2863348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Altered hepatic blood flow and drug disposition.
    Nies AS; Shand DG; Wilkinson GR
    Clin Pharmacokinet; 1976; 1(2):135-55. PubMed ID: 13954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of vitamin K3 on the first-pass elimination of propranolol in the rat.
    Ishida R; Usui T; Fukushima Y; Fujita S; Suzuki T
    J Pharm Sci; 1985 May; 74(5):578-81. PubMed ID: 4020639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The evaluation of the drug-metabolizing capacity in patients with diabetes mellitus.
    Salmela PI; Sotaniemi EA; Pelkonen RO
    Diabetes; 1980 Oct; 29(10):788-94. PubMed ID: 7439538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of sotalol during pregnancy.
    O'Hare MF; Leahey W; Murnaghan GA; McDevitt DG
    Eur J Clin Pharmacol; 1983; 24(4):521-4. PubMed ID: 6861867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of food on hepatic blood flow: implications in the "food effect" phenomenon.
    Svensson CK; Edwards DJ; Mauriello PM; Barde SH; Foster AC; Lanc RA; Middleton E; Lalka D
    Clin Pharmacol Ther; 1983 Sep; 34(3):316-23. PubMed ID: 6883907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative antihypertensive effects and tissue distribution of beta adrenergic blocking drugs.
    Garvey HL; Ram N
    J Pharmacol Exp Ther; 1975 Jul; 194(1):220-33. PubMed ID: 1151751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The disposition of propranolol. 8. General implications of the effects of liver blood flow on elimination from the perfused rat liver.
    Branch RA; Nies AS; Shand DG
    Drug Metab Dispos; 1973; 1(5):687-90. PubMed ID: 4149707
    [No Abstract]   [Full Text] [Related]  

  • 40. Drug metabolism in man: in vivo and in vitro correlations.
    Sotaniemi EA; Pelkonen RO; Ahokas J; Ahlqvist J; Hokkanen OT
    Arch Toxicol Suppl; 1978; (1):339-42. PubMed ID: 277127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.